As of October 5, 2021, Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2021-11-04 |
2021-09 |
-0.09 |
N/A |
N/A |
N/A |
2021-08-05 |
2021-06 |
-0.1 |
N/A |
N/A |
N/A |
2021-05-12 |
2021-03 |
-0.1 |
N/A |
N/A |
N/A |
2021-03-03 |
2020-12 |
-0.13 |
N/A |
N/A |
N/A |
2020-10-29 |
2020-09 |
-0.15 |
N/A |
N/A |
N/A |
2020-08-04 |
2020-06 |
-0.2 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2021-05-25 |
Craig-Hallum |
Downgrade |
Buy |
Hold |
2021-05-25 |
JMP Securities |
Downgrade |
Outperform |
Market Perform |
2020-10-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2020-03-03 |
Craig-Hallum |
Upgrade |
|
Buy |
2020-02-26 |
Oppenheimer |
Upgrade |
|
Outperform |
2019-09-25 |
Evercore ISI Group |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2021-01-06 |
COHEN FREDRIC J |
Officer |
218.93K |
Stock Award(Grant) |
2021-05-17 |
GILL DAVID N. |
Director |
95.82K |
Stock Award(Grant) |
2021-05-17 |
HERMANSEN STEINEGER HILDE |
Director |
82.02K |
Stock Award(Grant) |
2021-01-06 |
JOHNSON JOHN H |
Chief Executive Officer |
1.01M |
Stock Award(Grant) |
2021-03-02 |
KOLLENDER RICHARD S |
President |
327.50K |
Stock Award(Grant) |
2021-05-17 |
KONG GARHENG |
Director |
81.76K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2021-06-29 |
Caxton Corporation |
8.08M |
24.01M |
11.92% |
2021-06-29 |
NEA Management Company, LLC |
4.14M |
12.30M |
6.11% |
2021-06-29 |
Stonepine Capital Management, LLC |
3.31M |
9.82M |
4.87% |
2021-06-29 |
Rubric Capital Management LP |
2.70M |
8.01M |
3.97% |
2021-06-29 |
Vanguard Group, Inc. (The) |
2.20M |
6.53M |
3.24% |
2021-06-29 |
Morgan Stanley |
1.96M |
5.81M |
2.89% |
Report Date |
Organization |
Position |
Value |
Percentage |
2021-06-29 |
Vanguard Total Stock Market Index Fund |
1.38M |
4.09M |
2.03% |
2021-06-29 |
Vanguard Extended Market Index Fund |
688.71K |
2.05M |
1.02% |
2021-07-30 |
DFA U.S. Small Cap Series |
292.25K |
698.48K |
0.43% |
2021-08-30 |
Fidelity Extended Market Index Fund |
264.04K |
594.10K |
0.39% |
2021-08-30 |
iShares Micro Cap ETF |
126.23K |
284.01K |
0.19% |
2021-08-30 |
Principal U.S. Small Cap Multi Factor Index ETF |
94.31K |
212.19K |
0.14% |